



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: office@baishideng.com
<https://www.wjgnet.com>

JOURNAL EDITORIAL BOARD'S REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 88660

Title: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Journal Editor-in-Chief/Associate Editor/Editorial Board Member: Kai Wang

Country/Territory: China

Editorial Director: Jia-Ping Yan

Date accepted review: 2023-12-06 14:22

Date reviewed: 2023-12-06 14:23

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	language polishing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Major revision

JOURNAL EDITORIAL BOARD COMMENTS TO AUTHORS

The present meta-analysis was overall well designed and conducted. The results are of clinical importance.

JOURNAL EDITORIAL BOARD'S REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 88660

Title: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Journal Editor-in-Chief/Associate Editor/Editorial Board Member: Shuai Gao

Country/Territory: China

Editorial Director: Jia-Ping Yan

Date accepted review: 2023-12-09 14:22

Date reviewed: 2023-12-09 14:22

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	language polishing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Major revision

JOURNAL EDITORIAL BOARD COMMENTS TO AUTHORS

In this manuscript, the authors presented a systematic review and meta-analysis on the efficacy and safety of bamlanivimab in the treatment of coronavirus disease 2019 (COVID-19). A significant difference was observed between the bamlanivimab and standard of care/placebo groups in terms of mortality rate, hospitalization rate, and emergency department visits. While the two groups exhibited no significant difference in terms of intensive care unit admission. These results suggested that bamlanivimab might be effective and safe for the treatment of COVID-19. Overall, the manuscript is well prepared. The language should be edited carefully.

JOURNAL EDITORIAL BOARD'S REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 88660

Title: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic review and meta-analysis

Journal Editor-in-Chief/Associate Editor/Editorial Board Member: Kai Wang

Country/Territory: China

Editorial Director: Jia-Ping Yan

Date accepted review: 2023-12-23 14:06

Date reviewed: 2023-12-23 14:09

Review time: 1 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	language polishing	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Major revision

JOURNAL EDITORIAL BOARD COMMENTS TO AUTHORS

The present study investigated the efficacy and safety of bamlanivimab in the treatment of patients with coronavirus disease 2019 (COVID - 19) by meta-analysis. The study was overall well conducted and of clinical significance.